Glioblastoma is the most common and most aggressive primary brain tumor in adults, which poorly responds to current therapies and is inevitably fatal. Therefore, there is an urgent need for a better understanding of targetable molecular mechanisms at different disease stages and for novel treatment options. Epigenetic mechanisms are potential therapeutic targets due to their reversible nature. However, the gene regulatory landscape, comprising epigenetic alterations as well as transcriptional and chromatin regulators, in glioblastoma at different disease stages and upon chemotherapy and irradiation is largely unknown.
This project will address this gap of knowledge using cutting-edge technologies in genomics, single-cell transcriptomics and genome engineering as well as functional studies with state-of-the-art in vitro and in vivo models and patient samples. The project is carried out in the Laboratories of Prof. Dr. T. Baubec at the University of Zurich and Prof. Dr. M. Weller at the University Hospital Zurich and will involve interactions with different research groups and facilities from the research network of Zurich.
Individuals must have a PhD or MD-PhD degree, strong computational skills, excellent written and oral communication skills and be prepared to work in a dynamic team environment. Experience in the following technical areas is preferred: genomics, molecular and cell biology.